MOVIPREP RECEIVES APPROVAL IN RUSSIA

Back to media releases
Next media release
28 October 2014

CORPORATE PRESS RELEASE
 

MOVIPREP® RECEIVES APPROVAL IN RUSSIA
 


London, Tuesday 28 October, 07:00 GMT. Norgine B.V. announced today that its partner Takeda has received approval in Russia for MOVIPREP® (2L polyethylene glycol + ascorbate) for bowel cleansing prior to any clinical procedures requiring a clean bowel. The approval was granted on 22 September 2014 by The Ministry of Health of the Russian Federation.

MOVIPREP® was originally developed by Norgine. It is available in Europe through Norgine’s own infrastructure and in Eastern Europe, the US, India, Japan and Canada via partners.

Takeda acquired the commercialisation rights for MOVIPREP®  in 2011 for the Russian Federation and the Commonwealth of Independent States (CIS)*.

Paul Pay, VP Corporate and Business Development at Norgine said: “The Russian approval of MOVIPREP® is a key step in making the product available to patients in this major market.

Payment milestone is not disclosed.

* CIS unites: Azerbaijan, Armenia, Belarus, Georgia, Kazakhstan, Kyrgyzstan, Moldova, Russia, Tajikistan, Turkmenistan, Uzbekistan and Ukraine.

Ends

Notes to Editors:
 

For further information, please contact:
Charlotte Andrews: Tel: +44 (0)1895 453669, Mob: +44 (0)7714 061485
Peter Martin: Tel: +44 (0)1895 453744, Mob: +44 (0)7799 078744
Follow us @Norgine

About Norgine
Norgine is a European specialist pharmaceutical company that has been established for over 100 years. In 2013, Norgine’s total revenue was €274 million and the company employs over 1,000 people.

Norgine provides expertise and ‘know how’ in Europe to develop, manufacture and market products that offer real value to healthcare professionals, payers and patients. Norgine’s approach and infrastructure is integrated and focused upon ensuring that Norgine wins partnership opportunities for growth.

Norgine is headquartered in the Netherlands and its global operations are based in Amsterdam and in Harefield, UK. Norgine owns an R&D site in Hengoed, Wales and two manufacturing sites, one in Hengoed, Wales and one in Dreux, France.

For more information, please visit www.norgine.com

In 2012, Norgine established a complementary business Norgine Ventures, supporting innovative healthcare companies through the provision of debt-like financing in Europe and the US. For more information, please visit www.norgineventures.com

NORGINE and the sail logo are trademarks of the Norgine group of companies.